MBOT · Microbot Medical Inc.

Microbot Medical Inc. has achieved a critical commercial milestone with the successful execution of the limited market release (LMR) of its LIBERTY Endovascular Robotic System, marking the transition to full market release (FMR) in the U.S. This development is significant for investors as it demonstrates early market validation through adoption by prominent healthcare networks like Emory Healthcare and Tampa General Hospital, spanning dozens of hospitals. The system's proven use across diverse endovascular procedures—Prostate Artery Embolization (PAE), Uterine Fibroid Embolization (UFE), Genicular Artery Embolization (GAE), Y90 procedures, and peripheral interventions—highlights its versatility and addresses key physician needs for precision, reduced radiation exposure, short learning curve, and efficiency gains. In anticipation of FMR, the company has strategically bolstered its commercial infrastructure by doubling sales territories to eight, with plans to reach 12 by year-end 2026, signaling confidence in scalable demand and a potentially shorter sales cycle compared to traditional surgical robots. The timing aligns with the Society of Interventional Radiology (SIR) Annual Meeting in Toronto (April 11-15, 2026), where Microbot will debut LIBERTY at booth #423 to its primary U.S. target audience of over 8,000 interventional radiology professionals. Recent industry guidelines on radiation protection and ergonomic risks further underscore LIBERTY's value proposition as the only FDA-cleared, single-use, remotely operated system, positioning Microbot to capture market share in the growing endovascular robotics sector.